Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,401–2,500 of 15,747
COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
Fasching, C. L., Servellita, V., McKay, B., Nagesh, V., Broughton, J. P., Sotomayor-González, A., Wang, B., Brazer, N., Reyes, K. R., Streithorst, J. A., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00261-22 · Cited by 46
Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness
Mehraeen, E., Dadras, O., Afsahi, A. M., Karimi, A., MohsseniPour, M., Mirzapour, P., Barzegary, A., Behnezhad, F., Habibi, P., Salehi, M. A., et al. (2021) · Infectious Disorders - Drug Targets · doi:10.2174/1871526521666210923144837 · Cited by 47
Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine
Ackerman, M., Henry, D., Finon, A., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17248 · Cited by 45
Prevention of COVID-19 by mRNA-based vaccines within the general population of California
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., & Lewnard, J. A. (2021) · medRxiv · doi:10.1101/2021.04.08.21255135 · Cited by 43
Hess, S., Lancsar, E., Mariel, P., Meyerhoff, J., Song, F., van den Broek‐Altenburg, E. M., Alaba, O. A., Amaris, G., Arellana, J., Basso, L. J., et al. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.114800 · Cited by 52
Faermann, R., Nissan, N., Halshtok‐Neiman, O., et al. (2021) · Academic Radiology · doi:10.1016/j.acra.2021.06.003 · Cited by 45
Guglielmi, V., Colangeli, L., D’Adamo, M., & Sbraccia, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063183 · Cited by 49
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
Azzolini, E., Pozzi, C., Germagnoli, L., Oresta, B., Carriglio, N., Calleri, M., Selmi, C. F., Santis, M. D., Finazzi, S., Carlo‐Stella, C., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202201381 · Cited by 48
“Indeed, all of the vaccines approved so far have proven great efficacy in activating an immune response in healthy individuals (Polack et al, 2020; Walsh et al, 2020; Abu Jabal et al, 2021; Dagan et al, 2021; Haas et al, 2021; Voysey et al, 2021; Arunachalam et al, 2021a, 2021b), and we and others…”
BackgroundSkowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., El Adam, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab616 · Cited by 45
“Participants in these trials, however, were generally young and healthy with not more than 5% who were ≥75-years-old [2,3].”
InfluentialDuijster, J. W., Lieber, T., Pacelli, S., van Balveren, L., Ruijs, L. S., Raethke, M., Kant, A. C., & van Hunsel, F. P. A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1078736 · Cited by 44
“Large clinical trials for COVID-19 vaccines have accordingly included a proportionate number of females, however, a literature review showed that 30% of the studies with efficacy data and 34% of the studies with safety data presented sex-disaggregated outcomes (98, 99).”
ResultMore than a delivery system: the evolving role of lipid-based nanoparticles
Karmaker, S., Rosales, P. D., Tirumuruhan, B., Viravalli, A., & Boehnke, N. (2025) · Nanoscale · doi:10.1039/d4nr04508d · Cited by 63
Low case numbers enable long-term stable pandemic control without lockdowns
Contreras, S., Dehning, J., Mohr, S., Bauer, S., Spitzner, F. P., & Priesemann, V. (2021) · Science Advances · doi:10.1126/sciadv.abg2243 · Cited by 52
Hvidt, A. K., Baerends, E. A. M., Søgaard, O. S., Stærke, N. B., Raben, D., Reekie, J., Nielsen, H., Johansen, I. S., Wiese, L., Benfield, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.994160 · Cited by 46
“This difference may be explained by several factors, including variation in the composition of the lipid nanoparticles for packaging and delivery, the mRNA dose content (30 μg for BNT162b2 and 100 μg for mRNA1273) and/or the recommended time interval between the two primary vaccine doses (21 days for BNT162b2 and 28 d…”
BackgroundCOVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 53
Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review
Morva, A., Arroyo, A. B., Andreeva, L., Tapia‐Abellán, A., & Luengo‐Gil, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615760 · Cited by 53
Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings
Granata, V., Fusco, R., Setola, S. V., et al. (2021) · Biology · doi:10.3390/biology10030214 · Cited by 45
COVID-19 Infection in Children: Diagnosis and Management
Zhu, F. H., & Ang, J. Y. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00779-0 · Cited by 58
RIG-I-like receptors: Molecular mechanism of activation and signaling
Zheng, J., Shi, W., Yang, Z., Chen, J., Qi, A., Yang, Y., Deng, Y., Yang, D., Song, N., Song, B., et al. (2023) · Advances in immunology · doi:10.1016/bs.ai.2023.03.001 · Cited by 57
Webb, A. L. J., Welbourne, E. N., Evans, C. A., & Dickman, M. J. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465724 · Cited by 54
Jung, J., Zahmanova, G., Minkov, I. N., & Lomonossoff, G. P. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13813 · Cited by 49
“Currently, lipid nanoparticle-formulated, nucleoside-modified RNA vaccines (Polack et al., 2020; Walsh et al., 2020) and adenovirus-based vaccines that express the S protein within cells have been widely deployed to elicit immunity.”
BackgroundRafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
Kawai, A., Shimizu, T., Tanaka, H., Shichinohe, S., Anindita, J., Hirose, M., Kawahara, E., Senpuku, K., Shimooka, M., Mai, L. T. Q., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.032 · Cited by 55
Yin, J., Chen, Y., Li, Y., Wang, C., & Zhang, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.005 · Cited by 50
“…in clinical trials, and their proven efficacy was higher than 0% in preventing symptomatic laboratory-confirmed SARS-CoV-2 nfection, except for the CoronaVac vaccine, which only had proven ffectiveness of 51% ( Baden et al. , 2021 ; Kyriakidis et al. , 2021 ; allapaty, 2021 ; Vergnes, 2021 ).”
BackgroundNanomaterials in diagnostics, imaging and delivery: Applications from COVID-19 to cancer
Bardhan, N. M. (2022) · MRS Communications · doi:10.1557/s43579-022-00257-7 · Cited by 49
Braeye, T., Cornelissen, L., Catteau, L., Haarhuis, F., Proesmans, K., Ridder, K. D., Djiena, A., Mahieu, R., Leeuw, F. D., Dreuw, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.060 · Cited by 48
“This is a common approach to evaluate protection given the 14-day period necessary for the protection to become effective [2].”
BackgroundLi, Y., Bi, Y., Xiao, H., Yao, Y., Liu, X., Hu, Z., Duan, J., Yang, Y., Li, Z., Li, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1887767 · Cited by 45
Chrissian, A. A., Oyoyo, U. E., Patel, P., Beeson, W. L., Loo, L. K., Tavakoli, S., & Dubov, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.046 · Cited by 46
“Also, initial mRNA vaccine data suggesting Moderna’s greater reactogenicity were already available in early 2021 at the time of our survey [27,28,67].”
Harrington, P., de Lavallade, H., Doores, K. J., O’Reilly, A., Seow, J., Graham, C., Lechmere, T., Radia, D. H., Dillon, R. J., Shanmugharaj, Y., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01300-7 · Cited by 49
“Encouraging results have been observed from initial studies evaluating vaccines targeting the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2].”
BackgroundThe impact of Spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S., Heaney, J., Aldon, Y., Snitselaar, J., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.15.426849 · Cited by 45
COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and Morbidity
Prasad, N. K., Lake, R., Englum, B. R., Turner, D. J., Siddiqui, T., Mayorga‐Carlin, M., Sorkin, J. D., & Lal, B. K. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005176 · Cited by 48
“com for preventing COVID-19 infection.(1,2,18) Recent real-world data confirm the efficacy of the Pfizer and Moderna COVID-19 vaccines in preventing infection and have also shown effectiveness in reducing hospitalizations and mortality.”
BackgroundPolyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 52
Nanoparticles in clinical trials of COVID-19: An update
Rauf, A., Abu‐Izneid, T., Khalil, A. A., Hafeez, N., Olatunde, A., Rahman, M. M., Semwal, P., Al-Awthan, Y. S., Bahattab, O. S., Khan, I. N., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106818 · Cited by 49
Kawaguchi, Y., Kimura, M., Karaki, T., Tanaka, H., Ono, C., Ishida, T., Matsuura, Y., Hirai, T., Akita, H., Shimizu, T., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c10648 · Cited by 59
Cable News and COVID-19 Vaccine Compliance
Pinna, M., Picard, L., & Goessmann, C. (2021) · Scientific Reports · doi:10.1038/s41598-022-20350-0 · Cited by 62
Giesen, N., Sprute, R., Rüthrich, M. M., Khodamoradi, Y., Mellinghoff, S. C., Beutel, G., Lueck, C., Koldehoff, M., Hentrich, M., Sandherr, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.033 · Cited by 50
Röltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45
Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials
Brown, R. B. (2021) · Medicina · doi:10.3390/medicina57030199 · Cited by 44
“The New England Journal of Medicine also published clinical trial data on safety and efficacy for the BNT162b2 vaccine [12] and the mRNA-1273 vaccine [13], but with no mention of absolute risk reduction measures.”
MethodKlingler, J., Lambert, G. S., Itri, V., Liu, S. T. H., Bandrés, J. C., Enyindah-Asonye, G. M., Liu, X., Simon, V. R., Gleason, C., Kleiner, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759688 · Cited by 48
Little, J. S., Tandon, M., Hong, J., Nadeem, O., Sperling, A. S., Raje, N. S., Munshi, N. C., Frigault, M. J., Barmettler, S., & Hammond, S. P. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010524 · Cited by 50
Coppeta, L., Ferrari, C., Somma, G., Mazza, A., D’Ancona, U., Marcuccilli, F., Grelli, S., Aurilio, M. T., Pietroiusti, A., Magrini, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10020141 · Cited by 43
“The BNT162b2 vaccine contains a nucleoside-modified RNA that encodes the spike (S) protein of SARS-CoV-2 [4].”
BackgroundMeyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 45
Supekar, N. T., Shajahan, A., Gleinich, A. S., Rouhani, D. S., Heiß, C., Chapla, D. G., Moremen, K. W., & Azadi, P. (2021) · Glycobiology · doi:10.1093/glycob/cwab044 · Cited by 44
Impact of the COVID-19 pandemic on cardiac arrest systems of care
Kovach, C. P., & Perman, S. M. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000817 · Cited by 45
Szubert, A. J., Pollock, K. M., Cheeseman, H. M., Alagaratnam, J., Bern, H., Bird, O., Boffito, M., Byrne, R., Cole, T., Cosgrove, C. A., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101823 · Cited by 47
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 57
Takanashi, A., Pouton, C. W., & Al-Wassiti, H. A. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01024 · Cited by 49
DiRago, N. V., Li, M., Tom, T., Schupmann, W. D., Carrillo, Y., Carey, C., & Gaddis, S. M. (2021) · Journal of Urban Health · doi:10.1007/s11524-021-00589-0 · Cited by 49
“[2, 3, 4, 5, 6, 7, 8] Vaccines were free countrywide regardless of health insurance coverage.”
BackgroundComputational design of mRNA vaccines
Kim, Y.-A., Mousavi, K., Yazdi, A. K., Zwierzyna, M., Cardinali, M., Fox, D. M., Peel, T., Coller, J., Aggarwal, K., & Maruggi, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.024 · Cited by 51
SARS-CoV-2 Vaccines: Where Are We Now?
Flanagan, K. L., MacIntyre, C. R., McIntyre, P. B., & Nelson, M. R. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.016 · Cited by 46
“This efficacy must be against all infections, rather than symptomatic infection only, which is a common endpoint in COVID-19 vaccine clinical trials.(7,9) A key determinant of herd immunity, therefore, is whether vaccines can stop transmission by preventing both symptomatic and asymptomatic infection.”
Human Milk SARS-CoV-2 Antibodies up to 6 Months After Vaccination
Perez, S. E., Centeno, L. D. L., Cheng, W. A., Ruiz, C. J. M., Lee, Y., Congrave‐Wilson, Z., Powell, R. L. R., Stellwagen, L. M., & Pannaraj, P. S. (2022) · PEDIATRICS · doi:10.1542/peds.2021-054260 · Cited by 47
A pragmatic approach to COVID-19 vaccine passport
Sharif, A., Botlero, R., Hoque, N., Alif, S. M., Karim, M. N., & Islam, S. M. S. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-006956 · Cited by 44
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery
Wang, W., & Ouyang, D. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.015 · Cited by 50
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
Monschein, T., Hartung, H., Zrzavy, T., Barnett, M. H., Boxberger, N., Berger, T., Chataway, J., Bar‐Or, A., Rommer, P. S., & Zettl, U. K. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326839 · Cited by 47
Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England
Nafilyan, V., Bermingham, C. R., Ward, I. L., Morgan, J., Zaccardi, F., Khunti, K., Stanborough, J., Banerjee, A., & Doidge, J. (2023) · Nature Communications · doi:10.1038/s41467-023-36494-0 · Cited by 54
Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 46
“Two mRNA vaccines from Pfizer/BioNTech and Moderna are currently available—the former approved in Europe on 21 December 2020, the latter on 6 January 2021—with reported efficacy results in phase 2/3 trials of 95% (Pfizer/BioNTech) [1] and 94.”
BackgroundA Tutorial on Modern Bayesian Methods in Clinical Trials
Muehlemann, N., Zhou, T., Mukherjee, R., Hossain, M. I., Roychoudhury, S., & Russek‐Cohen, E. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-023-00515-3 · Cited by 59
Self-citationA Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
Dickey, J. B., Albert, E., Badr, M., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.06.003 · Cited by 44
“Large clinical trials of both BNT162b2 and mRNA1273 in more than 70,000 individuals in the United States showed good safety profiles for both of the mRNA-based vaccines and no reports of myocarditis (1,2).”
Impact of COVID-19 on Pediatric Immunocompromised Patients
Connelly, J. A., Chong, H., Esbenshade, A. J., Frame, D. G., Failing, C., Secord, E. A., & Walkovich, K. J. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.05.007 · Cited by 46
Vaira, L. A., VITO, A. D., Lechien, J. R., et al. (2021) · The Laryngoscope · doi:10.1002/lary.29964 · Cited by 44
“Vaccine safety has been widely demonstrated as well as their effectiveness in preventing the onset of severe coronavirus disease 2019 (COVID19).(1) The effectiveness in preventing symptomatic COVID-19 is instead variable between 73% and 91% in patients with complete vaccination and for the currently known variants.”
BackgroundHong, L., Alu, A., Yang, J., Ren, W., He, C., Lan, T., He, X., Yang, L., Li, J., Wang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01002-1 · Cited by 44
Adverse reactions to COVID‐19 vaccines: A practical approach
Rutkowski, K., Mirakian, R. M., Till, S. J., Rutkowski, R., & Wagner, A. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13880 · Cited by 44
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 57
Hernández–Díaz, S., Huybrechts, K. F., Chiu, Y., Yland, J. J., Bateman, B. T., & Hernán, M. Á. (2022) · Epidemiology · doi:10.1097/ede.0000000000001562 · Cited by 56
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 51
“Based on clinical trials in people aged 16 years and older, the vaccine has been shown to have an efficacy of 95% at protecting against COVID-19 in people without evidence of previous infection (Oliver et al., 2020; Polack et al., 2020).”
BackgroundMethodYanir, Y., Doweck, I., Shibli, R., Najjar‐Debbiny, R., & Saliba, W. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.4278 · Cited by 49
Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
Chen, Y., Li, C., Liu, F., Ye, Z., Song, W., Lee, A. C.-Y., Shuai, H., Lu, L., To, K. K., Chan, J. F., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2026741 · Cited by 46
“SARS-CoV-2 infection in clinical and animal studies [35,36,37].”
BackgroundIn Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease
Heinen, N., Klöhn, M., Steinmann, E., & Pfaender, S. (2021) · Viruses · doi:10.3390/v13050792 · Cited by 46
“Notably, the first vaccine authorization (mRNA vaccine BNT162B (Pfizer-BioNTech) that encodes for the full-length SARS-CoV-2 spike protein) was issued in December 2020 after successful completion of the third clinical phase [26], and was followed by approval of numerous other vaccines (e.”
BackgroundKlemis, V., Schmidt, T., Schub, D., Mihm, J., Marx, S., Abu‐Omar, A., Ziegler, L., Hielscher, F., Guckelmus, C., Urschel, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32321-0 · Cited by 48
Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
Garg, I., Sheikh, A. B., Pal, S., & Shekhar, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14040057 · Cited by 50
“While interpreting these findings, it is also important to note that these data were obtained in participants aged 50 years and older, and reactogenicity in the older age group might be higher than in the younger age group [55,56].”
BackgroundPrevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Santacatterina, M., Sanders, J. W., & Weintraub, W. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113575 · Cited by 44
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Augello, M., Bono, V., Rovito, R., Tincati, C., & Marchetti, G. C. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00647-z · Cited by 49
Rapaka, R. R., Hammershaimb, E. A., & Neuzil, K. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab213 · Cited by 49
Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 51
Wang, Z. J., She, R., Chen, X., Li, L., Li, L., Huang, Z., & Lau, J. T. F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917232 · Cited by 49
Hossain, M. E., Rana, M. J., Islam, S., Khan, M. A., Chakrobortty, S., Ema, N. S., & Bekun, F. V. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1968215 · Cited by 45
Meulewaeter, S., Aernout, I., Deprez, J., Engelen, Y., Velder, M. D., Franceschini, L., Breckpot, K., Calenbergh, S. V., Asselman, C., Boucher, K. L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.052 · Cited by 51
Kim, S., Ryu, H., Tai, S., Pedowitz, M., Rzasa, J. R., Pennachio, D. J., Hajzus, J. R., Milton, D. K., Myers‐Ward, R. L., & Daniels, K. M. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113803 · Cited by 52
van Oosten, L., Altenburg, J. J., Fougeroux, C. E., Geertsema, C., van den End, F., Evers, W. A. C., Westphal, A. H., Lindhoud, S., van den Berg, W., Swarts, D. C., et al. (2021) · mBio · doi:10.1128/mbio.01813-21 · Cited by 44
Cutaneous adverse reactions of COVID ‐19 vaccines: A systematic review
Qaderi, K., Golezar, M. H., Mardani, A., Mallah, M. A., Moradi, B., Kavoussi, H., Shamsabadi, A., & Golezar, S. (2022) · Dermatologic Therapy · doi:10.1111/dth.15391 · Cited by 53
COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis
Cavanna, L., Citterio, C., & Toscani, I. (2021) · Vaccines · doi:10.3390/vaccines9091048 · Cited by 45
“%) had received the BNT162b2 vaccine, and 62 (31”
BackgroundMethodInfluentialProfiles of current COVID-19 vaccines
Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 47
Morphological Characterization of Self-Amplifying mRNA Lipid Nanoparticles
Thelen, J. L., Leite, W. C., Urban, V. S., O’Neill, H., Grishaev, A., Curtis, J. E., Krueger, S., & Castellanos, M. M. (2024) · ACS Nano · doi:10.1021/acsnano.3c08014 · Cited by 47
RETRACTED: The Safety of COVID-19 Vaccinations—We Should Rethink the Policy
Walach, H., Klement, R. J., & Aukema, W. (2021) · Vaccines · doi:10.3390/vaccines9070693 · Cited by 70
“html#distribution-tab (accessed on 18 June 2021)), mostly the vector vaccination product developed by the Oxford vaccination group and marketed by AstraZeneca, Vaxzevria [2] (approximately 25% coverage in the EU), the RNA vaccination product of BioNTec marketed by Pfizer, Comirnaty [3,4] (approximately 60%), and the m…”
BackgroundMethodInfluentialRetractedMaine, C. J., Miyake-Stoner, S. J., Spasova, D. S., Picarda, G. G. A., Chou, A. C., Brand, E. D., Olesiuk, M. D., Domingo, C. C., Little, H. J., Goodman, T. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55843-9 · Cited by 62
Terpos, E., Trougakos, I. P., Karalis, V. D., Ntanasis‐Stathopoulos, I., Gumeni, S., Apostolakou, F., Sklirou, A. D., Gavriatopoulou, M., Skourti, S., Kastritis, E., et al. (2021) · Cells · doi:10.3390/cells10081942 · Cited by 46
Dispinseri, S., Lampasona, V., Secchi, M., Cara, A., Bazzigaluppi, E., Negri, D. R. M., Brigatti, C., Pirillo, M. F., Marzinotto, I., Borghi, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab055 · Cited by 46
Insights From Nanotechnology in COVID-19: Prevention, Detection, Therapy and Immunomodulation
Singh, P., Singh, D., Sa, P., Mohapatra, P., Khuntia, A., & Sahoo, S. K. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0004 · Cited by 50
Burack, D., Pereira, M. R., Tsapepas, D. S., Harren, P. A., FARR, M. A., Arcasoy, S. M., Cohen, D. J., Mohan, S., Emond, J. C., Hod, E. A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16541 · Cited by 48
Kantarcıoğlu, B., Iqbal, O., Walenga, J. M., Lewis, B., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Tafur, A. J., Ramacciotti, E., et al. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211021498 · Cited by 49
Lotan, I., Romanow, G., & Levy, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103189 · Cited by 44
“The approved vaccines have been tested in large-scale phase 3 trials, which recruited both healthy individuals and people with some chronic medical conditions (Polack et al., 2020).”
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
(2021) · doi:10.21203/rs.3.rs-143532/v1 · Cited by 628
Williams, S., Vusirikala, A., Ladhani, S., Olano, E. F. R. D., Iyanger, N., Aiano, F., Stoker, K., Gopalrao, G., John, L., Patel, B., et al. (2021) · Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · doi:10.2807/1560-7917.es.2021.26.27.2100626 · Cited by 39
“Clinical trial data at the time indicated that a single dose of the Comirnaty (BNT162b2 mRNA, BioNTechPfizer, Mainz, Germany/New York, United States (US)) vaccine was estimated to provide 89% protection from symptomatic disease [9] compared with 95% for two doses given 3 weeks apart [10].”
BackgroundRice, A., Verma, M. S., Shin, A., Zakin, L., Sieling, P. A., Tanaka, S., Balint, J. P., Dinkins, K., Adisetiyo, H., Morimoto, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94364-5 · Cited by 45
COVID-19: vaccination vs. hospitalization
Uzun, O., Akpolat, T., Varol, A., Turan, S., Bektaş, Ş. G., Çetinkaya, P. D., Dursun, M., Bakan, N., Ketencioğlu, B. B., Bayrak, M., et al. (2022) · Infection · doi:10.1007/s15010-021-01751-1 · Cited by 53
Serious complications of COVID-19 vaccines: A mini-review
Fragkou, P. C., & Dimopoulou, D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100145 · Cited by 43
“This incidence is 3.5 – 7 times higher than the incidence of general population [48,49].”
BackgroundInfluentialEftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 52
Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways
Tam, A., Kulkarni, J. A., An, K., Li, L., Dorscheid, D. R., Singhera, G. K., Bernatchez, P. N., Reid, G. S. D., Chan, K. Y. T., Witzigmann, D., et al. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106234 · Cited by 46
COVID-19 vaccination in patients with immune thrombocytopenia
Visser, C., Swinkels, M., van Werkhoven, E. D., Croles, F. N., Noordzij-Nooteboom, H. S., Eefting, M., Last-Koopmans, S. M., Idink, C., Westerweel, P. E., Santbergen, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006379 · Cited by 41
Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells
Aditham, A. J., Shi, H., Guo, J., Zeng, H., Zhou, Y., Wade, S. D., Huang, J., Liu, J., & Wang, X. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00569 · Cited by 46
Lipid-siRNA Organization Modulates the Intracellular Dynamics of Lipid Nanoparticles
Mo, Y., Keszei, A. F. A., Kothari, S., Liu, H., Pan, A., Kim, P., Bu, J., Kamanzi, A., Dai, D. L., Mazhab‐Jafari, M. T., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18308 · Cited by 50
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.